Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy
Main Article Content
Keywords
Actinic Keratosis, Field Treatment, Local Skin Reaction, Adherence, Treatment Duration, Patient Education
Abstract
Background: Actinic keratosis (AK) is a pre-malignant lesion with a poorly defined risk of progression to invasive squamous cell carcinoma (SCC). AKs are also associated with increased future risk of invasive SCC. However, there are many barriers to therapy adherence that may affect long-term treatment efficacy.
Objective: To review the current literature reporting known known factors of AK treatment non-adherence intrinsic to patient behavior and treatment regimens and re-examine how dermatologists can navigate these challenges.
Methods: A Medline literature search was performed to identify existing evidence regarding barriers to adherence with AK treatment regimens intrinsic to patient behavior, patient counseling, and treatment regimens pertinent for review.
Results & Discussion: Factors intrinsic to prescribed patient-applied therapy that can exacerbate non-adherence include: 1) length of treatment duration, 2) frequency of application, 3) complexity of treatment regimen, 4) duration and 5) severity of local skin reactions (LSR) and adverse reactions. Novel mechanisms of action that induce cellular apoptosis (as opposed to necrosis) via inhibition of tubulin polymerization and cell cycle arrest, may promote treatment regimen adherence and long-term outcomes. Dermatologists should also be conscious of how they counsel patients as insufficient counseling may also lead to poor adherence.
Conclusion: Dermatologists must understand the value of shorter course therapies and their positive impact on adherence and be well-versed in the mechanisms, efficacy and adverse events associated with treatment options. By doing so, dermatologists may best counsel and educate patients and devise regimens that address individualized patient concerns.
References
2. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7(4):231-6. doi: 10.2165/00128071-200607040-00004. PMID: 16901183.
3. Neri L, Peris K, Longo C, Calvieri S, Frascione P, Parodi A, Eibenschuz L, Bottoni U, Pellacani G; Actinic Keratosis - TReatment Adherence INitiative (AK-TRAIN) study group. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):93-107. doi: 10.1111/jdv.15142. Epub 2018 Jul 8. PMID: 29920789.
4. Kopasker, D., Kwiatkowski, A., Matin, R.N., Harwood, C.A., Ismail, F., Lear, J.T., Thomson, J., Hasan, Z., Wali, G.N., Milligan, A., Crawford, L., Ahmed, I., Duffy, H., Proby, C.M., Allanson, P.F., 2019. Patient preferences for topical treatment of actinic keratoses: a discrete‐choice experiment. British Journal of Dermatology 180, 902–909.. doi:10.1111/bjd.16801
5. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, Gould C, Gemmen E, Dall T; American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490-500. doi: 10.1016/j.jaad.2006.05.048. PMID: 16908356.
6. Yeung H, Baranowski ML, Swerlick RA, Chen SC, Hemingway J, Hughes DR, Duszak R Jr. Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015. JAMA Dermatol. 2018 Nov 1;154(11):1281-1285. doi: 10.1001/jamadermatol.2018.3086. PMID: 30326488; PMCID: PMC6248125.
7. Filosa A, Filosa G. Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G Ital Dermatol Venereol. 2015;150(4):379-84.
8. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management . Br J Dermatol. 1986;115:649-655.
9. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma . Lancet . 1988;1:795-797.
10. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991 Jul;127(7):1029-31. PMID: 2064402.
11. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol. 1991 Jul;127(7):1031-3. PMID: 2064403.
12. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23-4.
13. de Oliveira ECV, da Motta VRV, Pantoja PC, Ilha CSO, Magalhães RF, Galadari H, Leonardi GR. Actinic keratosis - review for clinical practice. Int J Dermatol. 2019 Apr;58(4):400-407. doi: 10.1111/ijd.14147. Epub 2018 Aug 2. PMID: 30070357.
14. Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N Engl J Med. 2019 Mar 7;380(10):935-946. doi: 10.1056/NEJMoa1811850. PMID: 30855743.
15. Dianzani C, Conforti C, Giuffrida R, Corneli P, di Meo N, Farinazzo E, Moret A, Magaton Rizzi G, Zalaudek I. Current therapies for actinic keratosis. Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3. PMID: 32012240.
16. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013 Dec 17;8:35-41. doi: 10.2147/PPA.S47126. PMID: 24379656; PMCID: PMC3872140.
17. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol. 1999;41(3 Pt 1):443-8
18. Keller B, Braathen LR, Marti HP, Hunger RE. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly. 2010 Jul 15;140:w13036. doi: 10.4414/smw.2010.13036. PMID: 20652847.
19. Foley P, Stockfleth E, Peris K, Basset-Seguin N, Cerio R, Antonio Sanches J, Guillen C, Farrington E, Lebwohl M. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatolog Treat. 2016 Nov;27(6):538-545. doi: 10.1080/09546634.2016.1178372. Epub 2016 May 10. PMID: 27161045.
20. Berker, D., Mcgregor, J.M., Mohd Mustapa, M.F., Exton, L.S., Hughes, B.R., Mchenry, P.M., Gibbon, K., Buckley, D.A., Nasr, I., Duarte Williamson, C.E., Swale, V.J., Leslie, T.A., Mallon, E.C., Wakelin, S., Ungureanu, S., Hunasehally, R.Y.P., Cork, M., Johnston, G.A., Natkunarajah, J., Worsnop, F.S., Chiang, N., Donnelly, J., Saunders, C., Brian, A.G., 2017. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. British Journal of Dermatology 176, 20–43.. doi:10.1111/bjd.15107
21. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013 Jan;68(1 Suppl 1):S10-9. doi: 10.1016/j.jaad.2012.09.053. PMID: 23228301.
22. Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013 Aug;169(2):250-9. doi: 10.1111/bjd.12343. PMID: 23550994.
23. AAD. Actinic keratoses: diagnosis and treatment. 2019. https://www.aad.org/public/diseases/scaly-skin/actinic-keratosis
24. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:17-20. doi: 10.1111/jdv.14091. PMID: 28263022.
25. Hansen JB, Larsson T, Dunkelly-Allen N, Veverka KA, Feldman SR. Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis. J Drugs Dermatol. 2020 Aug 1;19(8):756-762. doi: 10.36849/JDD.2020.5123. PMID: 32804451.
26. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998 May;19(5):723-9. doi: 10.1093/carcin/19.5.723. PMID: 9635856.
27. Elmets, C.A., Ledet, J.J., Athar, M., 2014. Cyclooxygenases: Mediators of UV-Induced Skin Cancer and Potential Targets for Prevention. Journal of Investigative Dermatology 134, 2497–2502.. doi:10.1038/jid.2014.192
28. Kopasker, D., Kwiatkowski, A., Matin, R.N., Harwood, C.A., Ismail, F., Lear, J.T., Thomson, J., Hasan, Z., Wali, G.N., Milligan, A., Crawford, L., Ahmed, I., Duffy, H., Proby, C.M., Allanson, P.F., 2019. Patient preferences for topical treatment of actinic keratoses: a discrete‐choice experiment. British Journal of Dermatology 180, 902–909.. doi:10.1111/bjd.16801
29. Werner RN, Jacobs A, Rosumeck S, Erdmann R, Sporbeck B, Nast A.Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International Leagueof Dermatological Societies in cooperation with the European Dermatol-ogy Forum.J Eur Acad Dermatol Venereol2015;29: e1–e66
30. Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, Turkoz A, Kopan R, Schaffer A, Saavedra AP, Wallendorf M, Cornelius LA, Demehri S, “Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy,” J Clin Invest. 2017 Jan 3;127(1):106-116. doi: 10.1172/JCI89820. Epub 2016 Nov 21.
31. Smolinski, M.P., Bu, Y., Clements, J., Gelman, I.H., Hegab, T., Cutler, D.L., Fang, J.W.S., Fetterly, G., Kwan, R., Barnett, A., Lau, J.Y.N., Hangauer, D.G., 2018. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry 61, 4704–4719.. doi:10.1021/acs.jmedchem.8b00164
32. Niu L, Yang J, Yan W, Yu Y, Zheng Y, Ye H, Chen Q, Chen L. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity. J Biol Chem. 2019 Nov 29;294(48):18099-18108. doi: 10.1074/jbc.RA119.010732. Epub 2019 Oct 18. PMID: 31628188; PMCID: PMC6885616.
33. Blauvelt, A., Kempers, S., Forman, S., Lain, E., & Bruce, S. (2020). Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies. SKIN The Journal of Cutaneous Medicine, 4(5), s63. https://doi.org/10.25251/skin.4.supp.62
34. Blauvelt, A., Kempers, S., Schlesinger, T., Lain, E., Wang, H., Cutler, D., Lebwohl, M., Fang, J., & Kwan, R. (2020). Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine, 4(6), s121. https://doi.org/10.25251/skin.4.supp.121
35. Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040. PMID: 33567191.
36. Berry, K., Butt, M., Kirby, J.S., 2017. Influence of Information Framing on Patient Decisions to Treat Actinic Keratosis. JAMA Dermatology 153, 421.. doi:10.1001/jamadermatol.2016.5245
37. Freeman, S., Bettencourt, M., Corliss, M., Dunkelly-Allen, N., & Veverka, K. A. (2020). Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis. SKIN The Journal of Cutaneous Medicine, 4(5), s65. https://doi.org/10.25251/skin.4.supp.64
38. Grada, A., Feldman, S.R., Bragazzi, N.L., Damiani, G., 2021. Patient‐reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatologic Therapy.. doi:10.1111/dth.14833
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.